<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25029655</article-id>
      <article-id pub-id-type="pmc">4109204</article-id>
      <article-id pub-id-type="publisher-id">S1806-37132014000300313</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132014000300015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Simultaneous interstitial pneumonitis and cardiomyopathy induced by
venlafaxine<xref ref-type="fn" rid="fn01">*</xref>
<xref ref-type="fn" rid="fn02">**</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Pedro Gon&#xE7;alo</given-names>
          </name>
          <role>Physician</role>
          <aff>Department of Pulmonology, Coimbra Hospital and University Center, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Susana</given-names>
          </name>
          <role>Physician</role>
          <aff>Department of Cardiology, Advanced Heart Failure Treatment Unit, Coimbra
Hospital and University Center, Coimbra, <country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Nuno</given-names>
          </name>
          <role>Physician</role>
          <aff>Department of Anatomopathology, Coimbra Hospital and University Center, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Ant&#xF3;nio Jorge</given-names>
          </name>
          <role>Physician</role>
          <aff>Department of Pulmonology, Coimbra Hospital and University Center, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Franco</surname>
            <given-names>F&#xE1;tima</given-names>
          </name>
          <role>Physician</role>
          <aff>Department of Pulmonology, Coimbra Hospital and University Center, Coimbra,
<country>Portugal</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to:</bold> Pedro Gon&#xE7;alo Ferreira Avenida Fernando Namora, 89 3&#xBA;
esquerdo, 3030-185, Coimbra, Portugal Tel. 035 196 6523825. E-mail:
<email>p_goncalof@hotmail.com</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Financial support: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <issue>3</issue>
      <fpage>313</fpage>
      <lpage>318</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>8</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an
antidepressant. Interindividual variability and herb-drug interactions can lead to
drug-induced toxicity. We report the case of a 35-year-old female patient diagnosed
with synchronous pneumonitis and acute cardiomyopathy attributed to venlafaxine. The
patient sought medical attention due to dyspnea and dry cough that started three
months after initiating treatment with venlafaxine for depression. The patient was
concomitantly taking <italic>Centella asiatica</italic> and <italic>Fucus
vesiculosus</italic> as phytotherapeutic agents. Chest CT angiography and chest
X-ray revealed parenchymal lung disease (diffuse micronodules and focal ground-glass
opacities) and simultaneous dilated cardiomyopathy. Ecocardiography revealed a left
ventricular ejection fraction (LVEF) of 21%. A thorough investigation was carried
out, including BAL, imaging studies, autoimmune testing, right heart catheterization,
and myocardial biopsy. After excluding other etiologies and applying the Naranjo
Adverse Drug Reaction Probability Scale, a diagnosis of synchronous
pneumonitis/cardiomyopathy associated with venlafaxine was assumed. The herbal
supplements taken by the patient have a known potential to inhibit cytochrome P450
enzyme complex, which is responsible for the metabolization of venlafaxine. After
venlafaxine discontinuation, there was rapid improvement, with regression of the
radiological abnormalities and normalization of the LVEF. This was an important case
of drug-induced cardiopulmonary toxicity. The circumstantial intake of inhibitors of
the CYP2D6 isoenzyme and the presence of a CYP2D6 slow metabolism phenotype might
have resulted in the toxic accumulation of venlafaxine and the subsequent clinical
manifestations. Here, we also discuss why macrophage-dominant phospholipidosis was
the most likely mechanism of toxicity in this case.</p>
      </abstract>
      <kwd-group>
        <kwd>Cardiomyopathy, dilated</kwd>
        <kwd>Lung diseases, interstitial</kwd>
        <kwd>Antidepressive agents, second-generation</kwd>
        <kwd>Herb-drug interactions</kwd>
      </kwd-group>
      <counts>
        <fig-count count="3"/>
        <ref-count count="22"/>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Drug-induced lung and heart disease can result from individual drug toxicity or
drug-to-drug interactions, with impairment of kinetics and metabolization.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>) </sup>The causal link between drug intake and an idiosyncratic reaction is
usually difficult to recognize, especially in cases of patients treated with multiple
medications.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> Therefore, high clinical suspicion and a thorough study are often
necessary. The molecular basis of toxic lung injury is still poorly defined for the
majority of the presently known offending drugs.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
      <p>We report the third case of a patient with synchronous interstitial pneumonitis and
acute cardiomyopathy induced by venlafaxine, with a new insight regarding the potential
lesion mechanism.</p>
      <sec>
        <title>Case report</title>
        <p>A 35-year-old female patient presented with progressive dyspnea over the previous
three months, New York Heart Association (NYHA) functional class III, myalgia, and
dry cough. She was hospitalized and submitted to CT angiography of the chest, which
excluded pulmonary thromboembolic disease but revealed hazy parenchymal micronodules,
thickening of interlobular septa, and subtle bilateral areas of ground-glass
attenuation, mainly in the upper lobes, without adenopathies or pleuropericardial
effusion (<xref ref-type="fig" rid="f01">Figure 1</xref>). A chest X-ray revealed a
mixed (reticular and micronodular) pattern and cardiomegaly (<xref ref-type="fig" rid="f02">Figure 2</xref>). Simultaneously, she was diagnosed with subacute severe
heart failure due to a dilated cardiomyopathy.</p>
        <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Chest CT scans at admission revealing hazy parenchymal micronodules
(short arrows) with thickening of interlobular septa and subtle diffuse
areas of ground glass attenuation (long arrows).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf01"/></fig>
</p>
        <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>In A, a chest X-ray taken at admission showing a mixed interstitial
pattern (reticular and micronodular) and cardiomegaly. In B, a chest X-ray
taken at discharge showing the normalization of the lung fields and of the
cardiac silhouette.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf02"/></fig>
</p>
        <p>The patient had a history of depression and was started on a slow-release formulation
of venlafaxine three months prior. For the last year, she had been taking
<italic>Centella asiatica</italic> and <italic>Fucus vesiculosus</italic> as
phytotherapeutic supplements for weight loss. The patient had no history of smoking,
alcohol use, or illicit drug use. Previous medical examinations had been negative for
heart disease, and there was neither a relevant family history nor a history of
occupational exposure.</p>
        <p>Clinical examination revealed apyrexia, mild hypotension, and an SpO<sub>2</sub> of
94%. On auscultation, there were crackles at both lung bases, with a grade II/VI
holosystolic murmur typical of mitral regurgitation. The jugular vein was not
turgescent, nor was there hepatomegaly or peripheral edema.</p>
        <p>Electrocardiography showed a normal sinus rhythm, ventricular premature beats, and
T-wave inversion in leads V4-V6, referred to as "strain"; an initial left ventricular
ejection fraction (LVEF) of 21% was identified on radionuclide angiography; biatrial
dilatation, severe left ventricular enlargement (71/60 mm), and severely impaired
global systolic function (LVEF = 20%) were also found; moderate right ventricular
enlargement with systolic impairment-tricuspid annular plane systolic excursion of 15
mm (normal value, 15-20 mm), S' velocity of 0.06 m/s (normal value, &gt; 0.15
m/s)-and severe functional mitral and tricuspid regurgitations were found on
echocardiography.</p>
        <p>Heart catheterization revealed normal coronary arteries and a cardiac index of 2.36 L
. min<sup>&#x2212;1</sup> . m<sup>&#x2212;2</sup> (normal value, 2.6-4.2 L . min<sup>&#x2212;1</sup> .
m<sup>&#x2212;2)</sup>. Myocardial biopsies presented mixed cellularity without fibrosis
or any other form of infiltration. Tests for DNA detection were negative for herpes
simplex virus, human herpesvirus 6 (HHV-6), HHV-8, cytomegalovirus, BK virus, and
Epstein-Barr virus.</p>
        <p>Pulmonary function test results were normal. However, the diffusion capacity was
slightly low (PaO<sub>2</sub>/FiO<sub>2</sub> = 320).</p>
        <p>Blood workup presented normal inflammatory parameters, euthyroidism, and a brain
natriuretic peptide level of 963.6 pg/mL (normal value, &lt; 100 pg/mL). Renal and
hepatic parameters, complement proteins, and urinary sediment were all normal. The
serological panel was negative for HIV, syphilis, <italic>Mycoplasma</italic> sp.,
<italic>Coxiella</italic> sp., cytomegalovirus, Epstein-Barr virus, parvovirus
B19, and HHV-6. The results of testing for autoimmune disease were unremarkable.</p>
        <p>Bronchoscopy results were normal. The BAL fluid presented normal cellularity, a low
CD4/CD8 lymphocyte ratio (0.7), and a massive presence of foamy macrophages (<xref ref-type="fig" rid="f03">Figure 3</xref>). The microbiological study on BAL fluid
was negative. No transbronchial lung biopsies were obtained, because of ventricular
tachycardia during the examination.</p>
        <p>
<fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Photomicrograph showing foamy macrophages in the BAL fluid
(May-Gr&#xFC;mwald-Giemsa; magnification, &#xD7;400).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf03"/></fig>
</p>
        <p>The patient was started on standard therapy without improvement. Inotropic support
was then initiated. However, no improvement was seen over the course of a week. At
that time, the decision was made to discontinue venlafaxine. Two weeks later, an HRCT
revealed notorious improvement, with only a few centrilobular nodules remaining in
the right lower lobe. Together with that radiological upswing, there was an overall
improvement, and the LVEF was up to 35% at discharge.</p>
        <p>Four months later, the patient presented with an LVEF close to normal (50%), NYHA
functional class I, maintaining only mild left ventricle enlargement (60/40 mm), and
mild mitral regurgitation. Most of the cardiac medications were therefore
discontinued.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>There have been various reports on adverse effects related to venlafaxine. Acute and
subacute interstitial pneumonitis have been reported<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>-</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> as have cases of eosinophilic pneumonia,<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> although the mechanisms involved have yet to be elucidated.</p>
      <p>The diagnosis of drug-induced interstitial lung disease is hindered by its clinical
nonspecificity, interindividual variations, the confounding effect of comorbidities, and
treatment with multiple medications.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> In addition, cases of venlafaxine-induced acute heart failure have been
described, some even in previously healthy patients under standard dosing
regimens.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> One group of authors reported dilated cardiomyopathy and cardiogenic shock
in a patient with previously normal heart function, with recovery of the LVEF after the
discontinuation of the medication. <sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Using the Naranjo Adverse Drug Reaction Probability Scale,<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> a probable link with venlafaxine was found.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Although the mechanism of heart injury is still not fully understood,
drug-induced inhibition of myocardial norepinephrine reuptake and blockade of cardiac
sodium channels have been reported.<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>
</p>
      <p>The cytochrome P450 (CYP) superfamily is present in human lung tissue and participates
in the enzymatic inactivation of numerous xenobiotics.<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup> Metabolic differences related to CYP polymorphisms contribute to
interindividual variability reflected in drug responses and unexpected
toxicity.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> One group of authors showed that, among 59 patients with drug-induced
interstitial lung disease, 54 (91.5%) had at least one of the studied CYP variant
genes.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> In 87% of those patients, the presence of such genes was found to be
relevant to their clinical profile.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
      <p>Venlafaxine is an antidepressant that is metabolized to O-desmethylvenlafaxine (ODV) by
the isoenzyme CYP2D6 and, to a lesser extent, by CYP3A4.<sup>(</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> For numerous psychotropic drugs, CYP2D6 is a high-affinity/low-capacity
enzyme whose polymorphisms can phenotypically determine slow, extended, or rapid
metabolization.<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup> Because a less functional variant might be able to precipitate severe
manifestations,<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> the administration of venlafaxine to CYP2D6 slow metabolizers or the
coadministration with CYP2D6 inhibitor drugs carries the risk of drug accumulation and
subsequent cellular/organic insult.<sup>(</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup> It has been shown that <italic>Centella asiatica</italic> can induce
moderate-to-strong inhibition of CYP2D6<sup>(</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup> and that <italic>Fucus vesiculosus</italic> can also inhibit the cytochrome
P450 enzyme complex. <sup>(</sup>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup> Accordingly, although the CYP2D6 profile of our patient had not been
tested, we hypothesize that she was a CYP2D6 slow metabolizer or that the inhibitory
action of the concomitant use of the herbal drugs contributed to venlafaxine
accumulation, leading to cardiopulmonary toxicity.</p>
      <p>Drug-induced phospholipidosis (DIP) is characterized by intracellular accumulation of
phospholipids in various body tissues and formation of lamellar bodies, leading to a
foamy macrophage appearance at light microscopy. <sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> It can be caused by over 50 drugs sharing a particular molecular structure,
with hydrophobic and hydrophilic regions, denominated cationic amphiphilic drugs
(CADs).<sup>(</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup> The venlafaxine formulation used by our patient was analyzed by the
Department of Organic Chemistry, University of Coimbra, Portugal. The patient was taking
a formulation of the racemic mixture of
(R/S)-1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol hydrochloride. Its
structure combines a hydrophilic cationic component (terminal amine and tertiary alcohol
groups) with a hydrophobic nonpolar component (aromatic ring methoxylation and
cyclohexyl group), conferring amphiphilicity.<sup>(</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup> In addition, it has a cationic property,<sup>(</sup>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>)</sup> because ODV presents an acidic phenol group (from the hydrolysis of the
methyl ethers connected to the aromatic ring) and the amine group can undergo extensive
intramolecular protonation, becoming a CAD by staying in zwitterion form (negative
aromatic-O- and positive H+ amine groups). This fact, supported by the clinical context
and the massive presence of foamy macrophages observed in the BAL fluid, strongly
suggests a mechanism of venlafaxine-induced phospholipidosis.</p>
      <p>Although DIP can occur from hours to months after the beginning of
treatment,<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> its precise mechanisms have yet to be completely clarified. Lysosomes act
as a place of accumulation of CADs and phospholipids because of their direct connection
with CADs and the inhibition of phospholipases.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>,</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup> Because lysosomes participate in a wide variety of cellular processes,
there might be ionic transport impairment, oxidative phosphorylation, heterophagy,
autophagy, organelle recycling, cell membrane repairing, and cell cycle regulation.
Three recognized damage patterns can occur: macrophage-dominant phospholipidosis (the
commonest), parenchymal-cell-dominant phospholipidosis, and localized
phospholipidosis.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>
</p>
      <p>Another typical feature of DIP is its reversibility after drug
discontinuation.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> Because phospholipid levels normalize and drug efflux occurs, organic,
functional, and radiological abnormalities usually improve from weeks to
months.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> Reversibility is usually complete, but permanent damage can subside in
cases of more severe organic injury.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
      <p>The present case details the occurrence of cardiopulmonary toxicity, which was probably
associated with venlafaxine. The case occurred in a previously healthy 35-year-old
patient submitted to exhaustive investigation after the exclusion of other possible
causes. Only two similar cases have been reported in the literature.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>
</p>
      <p>We recognized the concomitant intake of two herbal drugs known to inhibit the specific
metabolizing isoenzyme of venlafaxine, which would explain the accumulation of
venlafaxine and ODV to toxic levels. The strong temporal connection between the drug
intake and the clinical manifestations and, conversely, between the drug discontinuation
and the rapid improvement in lung abnormalities and heart function, provides additional
support for that hypothesis. For ethical reasons, rechallenge with venlafaxine was not
carried out. After an objective analysis, considering the Naranjo Adverse Drug Reaction
Probability Scale,<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> we made a diagnosis of venlafaxine-induced cardiopulmonary toxicity.</p>
      <p>A DIP could be the mechanism of toxicity, because venlafaxine is a potential CAD, as
well as because there were striking quantities of foamy macrophages in the BAL fluid, a
low CD4/CD8 T lymphocyte ratio in the blood and BAL fluid, and features that were
consistent with a "macrophage-dominant phospholipidosis" subtype pattern.</p>
      <p>The present case highlights the importance of high clinical suspicion for the timely
recognition of drug-induced cardiopulmonary toxicity, especially in cases of initially
unexplained disease. Prompt discontinuation of the drug usually results in remarkable
clinical and prognostic improvement.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors would like to thank Professor V&#xED;tor Sobral of the Department of Chemistry of
the University of Coimbra for his vital contribution in the analysis of the chemical
structure of venlafaxine.</p>
    </ack>
    <fn-group>
      <fn id="fn01" fn-type="supported-by">
        <label>*</label>
        <p>
<sup>Study</sup> carried out in the Department of Pulmonology, Department of
Cardiology, Advanced Heart Failure Treatment Unit, and Department of
Anatomopathology, Coimbra Hospital and University Center, Coimbra, Portugal. </p>
      </fn>
      <fn id="fn02" fn-type="other">
        <label>**</label>
        <p>A vers&#xE3;o completa em portugu&#xEA;s deste artigo est&#xE1; dispon&#xED;vel em
www.jornaldepneumologia.com.br</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nemery</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bast</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Borm</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bourke</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Camus</surname>
              <given-names>PH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interstitial lung disease induced by exogenous agents:
factors governing susceptibility</article-title>
          <source>Eur Respir J Suppl</source>
          <year>2001</year>
          <volume>32</volume>
          <fpage>30s</fpage>
          <lpage>42s</lpage>
          <pub-id pub-id-type="pmid">11816823</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wijnen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Drent</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nelemans</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kuijpers</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Koek</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Neef</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of cytochrome P450 polymorphisms in the development
of pulmonary drug toxicity</article-title>
          <source>Drug Saf</source>
          <year>2008</year>
          <volume>31</volume>
          <issue>12</issue>
          <fpage>1125</fpage>
          <lpage>1134</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2165/0002018-200831120-00008">http://dx.doi.org/10.2165/0002018-200831120-00008</ext-link>
          <pub-id pub-id-type="pmid">19026029</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wijnen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bekers</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Drent</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Relationship between drug-induced interstitial lung
diseases and cytochrome P450 polymorphisms</article-title>
          <source>Curr Opin Pul Med</source>
          <year>2010</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>496</fpage>
          <lpage>502</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MCP.0b013e32833c06f1">http://dx.doi.org/10.1097/MCP.0b013e32833c06f1</ext-link>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drent</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gorgels</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Hansell</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Bekers</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug-induced pneumonitis and heart failure
simultaneously associated with venlafaxine</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>167</volume>
          <issue>7</issue>
          <fpage>958</fpage>
          <lpage>961</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200207-739CR">http://dx.doi.org/10.1164/rccm.200207-739CR</ext-link>
          <pub-id pub-id-type="pmid">12663337</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>V&#xE1;zquez</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Carretero Quevedo</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Pneumonitis related to venlafaxine</article-title>
          <source>Psychosomatics</source>
          <year>2008</year>
          <volume>49</volume>
          <issue>1</issue>
          <fpage>84</fpage>
          <lpage>85</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1176/appi.psy.49.1.84">http://dx.doi.org/10.1176/appi.psy.49.1.84</ext-link>
          <pub-id pub-id-type="pmid">18212183</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Gillam</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Venlafaxine-associated interstitial
pneumonitis</article-title>
          <source>Pharmacotherapy</source>
          <year>2005</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>626</fpage>
          <lpage>629</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1592/phco.25.4.626.61029">http://dx.doi.org/10.1592/phco.25.4.626.61029</ext-link>
          <pub-id pub-id-type="pmid">15977923</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Border&#xED;as Clau</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marigil G&#xF3;mez</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Val Ad&#xE1;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Marc&#xE9;n Letosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Biescas L&#xF3;pez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garrapiz L&#xF3;pez</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity pneumonitis due to
venlafaxine</article-title>
          <source>Arch Bronconeumol</source>
          <year>2008</year>
          <volume>44</volume>
          <issue>10</issue>
          <fpage>571</fpage>
          <lpage>573</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1579-2129(08)60104-4">http://dx.doi.org/10.1016/S1579-2129(08)60104-4</ext-link>
          <pub-id pub-id-type="pmid">19006638</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleisch</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Blauer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gubler</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scherer</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Eosinophilic pneumonia and respiratory failure
associated with venlafaxine treatment</article-title>
          <source>Eur Respir J</source>
          <year>2000</year>
          <volume>15</volume>
          <issue>1</issue>
          <fpage>205</fpage>
          <lpage>208</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.00.15120500">http://dx.doi.org/10.1183/09031936.00.15120500</ext-link>
          <pub-id pub-id-type="pmid">10678647</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Priou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gagnadoux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Deh&#xE9;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hureaux</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Urban</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug-induced pneumonitis in a patient treated with
venlafaxine and propanolol [Article in French]</article-title>
          <source>Rev Mal Respir</source>
          <year>2008</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>610</fpage>
          <lpage>613</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0761-8425(08)71620-6">http://dx.doi.org/10.1016/S0761-8425(08)71620-6</ext-link>
          <pub-id pub-id-type="pmid">18535530</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charniot</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Vignat</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Monsuez</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Kidouche</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Avramova</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Artigou</surname>
              <given-names>JY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cardiogenic shock associated with reversible dilated
cardiomyopathy during therapy with regular doses of venlafaxine</article-title>
          <source>Am J Emerg Med</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>2</issue>
          <fpage>256.e1</fpage>
          <lpage>256.e5</lpage>
          <pub-id pub-id-type="pmid">20159409</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug
reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <issue>2</issue>
          <fpage>239</fpage>
          <lpage>245</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/clpt.1981.154">http://dx.doi.org/10.1038/clpt.1981.154</ext-link>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalifa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Daleau</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>aJ</surname>
              <given-names>Turgeon</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of sodium channel block by venlafaxine in
guinea pig ventricular myocites</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1999</year>
          <volume>291</volume>
          <issue>1</issue>
          <fpage>280</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="pmid">10490914</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Xenobiotic-metabolizing enzymes in human
lung</article-title>
          <source>Curr Drug Metab</source>
          <year>2006</year>
          <volume>7</volume>
          <issue>8</issue>
          <fpage>939</fpage>
          <lpage>948</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2174/138920006779010575">http://dx.doi.org/10.2174/138920006779010575</ext-link>
          <pub-id pub-id-type="pmid">17168693</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veefkind</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Haffmans</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Hoencamp</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Venlafaxine serum levels and CYP2D6
genotype</article-title>
          <source>Ther Drug Monit</source>
          <year>2000</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>202</fpage>
          <lpage>208</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00007691-200004000-00011">http://dx.doi.org/10.1097/00007691-200004000-00011</ext-link>
          <pub-id pub-id-type="pmid">10774634</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eichelbaum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Evert</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Influence of pharmacogenetics on drug disposition and
response</article-title>
          <source>Clin Exp Pharmacol Physiol</source>
          <year>1996</year>
          <volume>23</volume>
          <issue>10-11</issue>
          <fpage>983</fpage>
          <lpage>985</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1440-1681.1996.tb01154.x">http://dx.doi.org/10.1111/j.1440-1681.1996.tb01154.x</ext-link>
          <pub-id pub-id-type="pmid">8911746</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shams</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Arneth</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hiemke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dragicevic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CYP2D6 polymorphism and clinical effect of the
antidepressant venlafaxine</article-title>
          <source>J Clin Pharm Ther</source>
          <year>2006</year>
          <volume>31</volume>
          <issue>5</issue>
          <fpage>493</fpage>
          <lpage>502</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2710.2006.00763.x">http://dx.doi.org/10.1111/j.1365-2710.2006.00763.x</ext-link>
          <pub-id pub-id-type="pmid">16958828</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Abd-Rashid</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Ismail</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ismail</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mak</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Pook</surname>
              <given-names>PC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vitro modulatory effects on three major human
cytochrome P450 enzymes by multiple active constituents and extracts of Centella
asiatica</article-title>
          <source>J Ethnopharmacol</source>
          <year>2010</year>
          <volume>130</volume>
          <issue>2</issue>
          <fpage>275</fpage>
          <lpage>283</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jep.2010.05.002">http://dx.doi.org/10.1016/j.jep.2010.05.002</ext-link>
          <pub-id pub-id-type="pmid">20457244</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parys</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kehraus</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Glombitza</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Carmeli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klimo</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vitro chemopreventive potential of fucophlorethols
from the brown alga Fucus vesiculosus L. by anti-oxidant activity and inhibition
of selected cytochrome P450 enzymes</article-title>
          <source>Phytochemistry</source>
          <year>2010</year>
          <volume>71</volume>
          <issue>2-3</issue>
          <fpage>221</fpage>
          <lpage>229</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.phytochem.2009.10.020">http://dx.doi.org/10.1016/j.phytochem.2009.10.020</ext-link>
          <pub-id pub-id-type="pmid">19954804</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nonoyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fukuda</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced phospholipidosis-pathological aspects and
its prediction</article-title>
          <source>J Toxicol Pathol</source>
          <year>2008</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>9</fpage>
          <lpage>24</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1293/tox.21.9">http://dx.doi.org/10.1293/tox.21.9</ext-link>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Borlak</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced phospholipidosis</article-title>
          <source>FEBS Lett</source>
          <year>2006</year>
          <volume>580</volume>
          <issue>23</issue>
          <fpage>5533</fpage>
          <lpage>5540</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.febslet.2006.08.061">http://dx.doi.org/10.1016/j.febslet.2006.08.061</ext-link>
          <pub-id pub-id-type="pmid">16979167</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamal</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bukhari</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Muneer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shahzad</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Influence of external factors on self-aggregation of
amphiphilic antidepressant drug: a thermodynamic study</article-title>
          <source>J Chem Soc Pakistan</source>
          <year>2013</year>
          <volume>35</volume>
          <issue>2</issue>
          <fpage>262</fpage>
          <lpage>266</lpage>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balasubramaniam</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bindu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>VU</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Haldar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brzeczko</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Effect of superdisintegrants on dissolution of cationic
drugs</article-title>
          <source>Dissolut Technol</source>
          <year>2008</year>
          <volume>15</volume>
          <issue>2</issue>
          <fpage>18</fpage>
          <lpage>25</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pneumonite intersticial e miocardiopatia simult&#xE2;neas induzidas por
venlafaxina<xref ref-type="fn" rid="fn03">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Pedro Gon&#xE7;alo</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff> Servi&#xE7;o de Pneumologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Susana</given-names>
          </name>
          <role>M&#xE9;dica</role>
          <aff>Unidade de Tratamento de Insufici&#xEA;ncia Card&#xED;aca Avan&#xE7;ada, Servi&#xE7;o de
Cardiologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Nuno</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff>Servi&#xE7;o de Anatomopatologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra,
Coimbra, <country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Ant&#xF3;nio Jorge</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff>Servi&#xE7;o de Pneumologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra, Coimbra,
<country>Portugal</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Franco</surname>
            <given-names>F&#xE1;tima</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff>Servi&#xE7;o de Pneumologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra, Coimbra,
<country>Portugal</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c02"><bold>Endere&#xE7;o para correspond&#xEA;ncia:</bold> Pedro Gon&#xE7;alo Ferreira Avenida Fernando
Namora, 89 3&#xBA; esquerdo, 3030-185, Coimbra, Portugal Tel. 035 196 6523825. E-mail:
<email>p_goncalof@hotmail.com</email></corresp>
      </author-notes>
      <abstract>
        <p>A venlafaxina &#xE9; um inibidor de recapta&#xE7;&#xE3;o de serotonina e noradrenalina utilizado
como antidepressivo. A variabilidade individual ou intera&#xE7;&#xF5;es entre fitoter&#xE1;picos e
f&#xE1;rmacos podem causar toxicidade induzida por drogas. Relatamos o caso de uma
paciente de 35 anos diagnosticada com pneumonite intersticial e miocardiopatia
dilatada atribu&#xED;das &#xE0; venlafaxina. A paciente procurou atendimento m&#xE9;dico devido a
dispneia e tosse seca, que come&#xE7;aram tr&#xEA;s meses ap&#xF3;s iniciar tratamento com
venlafaxina para depress&#xE3;o. Concomitantemente tomava suplementos fitoter&#xE1;picos
contendo <italic>Centella asiatica</italic> e <italic>Fucus vesiculosus</italic>. A
radiografia e a CT de t&#xF3;rax revelaram doen&#xE7;a pulmonar parenquimatosa (micron&#xF3;dulos
difusos e opacidades em vidro fosco) e, simultaneamente, foi diagnosticada uma
miocardiopatia por ecocardiograma, que revelou uma fra&#xE7;&#xE3;o de eje&#xE7;&#xE3;o ventricular
esquerda (FEVE) de 21%. Uma investiga&#xE7;&#xE3;o ampla foi realizada, incluindo LBA, estudos
de imagem, detec&#xE7;&#xE3;o de doen&#xE7;as autoimunes, cateterismo card&#xED;aco direito e bi&#xF3;psia
mioc&#xE1;rdica. Ap&#xF3;s a exclus&#xE3;o de outras etiologias e a aplica&#xE7;&#xE3;o da Escala de
Probabilidade de Rea&#xE7;&#xF5;es Adversas a Medicamentos de Naranjo, foi assumido o
diagn&#xF3;stico de pneumonite/miocardiopatia s&#xED;ncronas associadas &#xE0; venlafaxina. J&#xE1; foi
demonstrado que os suplementos fitoter&#xE1;picos utilizados pela paciente podem inibir a
isoenzima do complexo enzim&#xE1;tico citocromo P450, respons&#xE1;vel pelo metabolismo da
venlafaxina. Ap&#xF3;s a descontinua&#xE7;&#xE3;o da venlafaxina, verificou-se uma r&#xE1;pida melhora
cl&#xED;nica com regress&#xE3;o das altera&#xE7;&#xF5;es radiol&#xF3;gicas e normaliza&#xE7;&#xE3;o da FEVE. Este &#xE9; um
importante caso de toxicidade cardiopulmonar induzida por droga. A administra&#xE7;&#xE3;o
circunstancial de inibidores da isoenzima CYP2D6 e a presen&#xE7;a de um fen&#xF3;tipo de
metaboliza&#xE7;&#xE3;o lenta de CYP2D6 podem ter resultado na acumula&#xE7;&#xE3;o t&#xF3;xica da venlafaxina
e na manifesta&#xE7;&#xE3;o cl&#xED;nica subsequente. Aqui, &#xE9; discutida a hip&#xF3;tese de a
fosfolipidose macrof&#xE1;gica ser o mecanismo de toxicidade.</p>
      </abstract>
      <kwd-group>
        <kwd>Cardiomiopatia dilatada</kwd>
        <kwd>Doen&#xE7;as pulmonares intersticiais</kwd>
        <kwd>Antidepressivos de segunda gera&#xE7;&#xE3;o/toxicidade</kwd>
        <kwd>Toxicidade de Drogas</kwd>
        <kwd>Intera&#xE7;&#xF5;es ervas-drogas</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>Doen&#xE7;a pulmonar e card&#xED;aca induzida por drogas pode resultar da toxicidade dos
f&#xE1;rmacos para o indiv&#xED;duo ou da intera&#xE7;&#xE3;o entre f&#xE1;rmacos, com comprometimento da
cin&#xE9;tica e do metabolismo.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> O nexo de causalidade entre a administra&#xE7;&#xE3;o de drogas e uma rea&#xE7;&#xE3;o
idiossincr&#xE1;tica &#xE9; geralmente dif&#xED;cil de reconhecer, especialmente em casos de
pacientes tratados com m&#xFA;ltiplos medicamentos.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> Portanto, s&#xE3;o frequentemente necess&#xE1;rios alta suspei&#xE7;&#xE3;o cl&#xED;nica e estudo
amplo. A base molecular da les&#xE3;o pulmonar t&#xF3;xica ainda &#xE9; pouco definida para a
maioria dos medicamentos ofensivos conhecidos atualmente.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
        <p>Relatamos o terceiro caso de paciente com pneumonite intersticial e miocardiopatia
dilatada induzidas pela venlafaxina, com uma nova percep&#xE7;&#xE3;o sobre o potencial
mecanismo de les&#xE3;o.</p>
      </sec>
      <sec>
        <title>Relato de caso</title>
        <p>Paciente do sexo feminino, 35 anos de idade, apresentava dispneia progressiva nos
&#xFA;ltimos tr&#xEA;s meses, classe funcional III da <italic>New York Heart
Association</italic> (NYHA), mialgia e tosse seca. Foi internada e submetida a
angiografia por TC de t&#xF3;rax, que excluiu doen&#xE7;a tromboemb&#xF3;lica pulmonar mas revelou
micron&#xF3;dulos parenquimatosos indistintos, espessamento dos septos interlobulares e
&#xE1;reas de atenua&#xE7;&#xE3;o em vidro fosco bilaterais e sutis, principalmente nos lobos
superiores, sem adenopatias ou derrame pleuroperic&#xE1;rdico (<xref ref-type="fig" rid="f04">Figura 1</xref>). A radiografia de t&#xF3;rax revelou padr&#xE3;o misto (reticular
e micronodular) e cardiomegalia (<xref ref-type="fig" rid="f05">Figura 2</xref>).
Simultaneamente, foi diagnosticada com insufici&#xEA;ncia card&#xED;aca subaguda grave causada
por miocardiopatia dilatada.</p>
        <p>
<fig id="f04" orientation="portrait" position="float"><label>Figura 1</label><caption><title> TC de t&#xF3;rax na admiss&#xE3;o hospitalar revelando micron&#xF3;dulos
parenquimatosos indistintos (setas curtas) com espessamento dos septos
interlobulares e &#xE1;reas de atenua&#xE7;&#xE3;o em vidro fosco difusas e sutis (setas
longas).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf01-pt"/></fig>
</p>
        <p>
<fig id="f05" orientation="portrait" position="float"><label>Figura 2</label><caption><title> Em A, radiografia de t&#xF3;rax na admiss&#xE3;o hospitalar mostrando padr&#xE3;o
intersticial misto (reticular e micronodular) e cardiomegalia. Em B,
radiografia de t&#xF3;rax na alta hospitalar mostrando a normaliza&#xE7;&#xE3;o dos campos
pulmonares e da &#xE1;rea card&#xED;aca.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf02-pt"/></fig>
</p>
        <p>Apresentava hist&#xF3;ria de depress&#xE3;o e havia iniciado tratamento com uma formula&#xE7;&#xE3;o de
libera&#xE7;&#xE3;o lenta de venlafaxina h&#xE1; tr&#xEA;s meses. Desde o ano anterior, estava tomando
suplementos fitoter&#xE1;picos de <italic>Centella asiatica</italic> e <italic>Fucus
vesiculosus</italic> para perda de peso. N&#xE3;o apresentava hist&#xF3;ria de tabagismo, de
uso de &#xE1;lcool ou de uso de drogas il&#xED;citas. Exames m&#xE9;dicos anteriores haviam sido
negativos para doen&#xE7;as card&#xED;acas, e n&#xE3;o havia hist&#xF3;ria familiar relevante nem
hist&#xF3;ria de exposi&#xE7;&#xE3;o ocupacional.</p>
        <p>O exame f&#xED;sico revelou apirexia, hipotens&#xE3;o leve e SpO<sub>2</sub> de 94%. Na
ausculta&#xE7;&#xE3;o, havia estertores crepitantes bibasais, com sopro holossist&#xF3;lico de grau
II/VI t&#xED;pico da regurgita&#xE7;&#xE3;o mitral. A veia jugular n&#xE3;o apresentava incha&#xE7;o; tampouco
havia hepatomegalia ou edema perif&#xE9;rico.</p>
        <p>O eletrocardiograma mostrou ritmo sinusal normal, batimentos ventriculares prematuros
e invers&#xE3;o da onda T em V4-V6, conhecida como "tens&#xE3;o"; uma fra&#xE7;&#xE3;o de eje&#xE7;&#xE3;o
ventricular esquerda (FEVE) de 21% foi identificada na angiografia de radionucl&#xED;deos;
tamb&#xE9;m foram encontradas dilata&#xE7;&#xE3;o biatrial, dilata&#xE7;&#xE3;o grave do ventr&#xED;culo esquerdo
(71/60 mm) e fun&#xE7;&#xE3;o sist&#xF3;lica global gravemente comprometida (FEVE = 20%); dilata&#xE7;&#xE3;o
moderada do ventr&#xED;culo direito com comprometimento sist&#xF3;lico - excurs&#xE3;o sist&#xF3;lica do
plano anular da valva tric&#xFA;spide de 15 mm (valor normal, 15-20 mm), velocidade de S'
de 0,06 m/s (valor normal, &gt; 0,15 m/s) - e regurgita&#xE7;&#xF5;es funcionais mitral e
tric&#xFA;spide graves foram encontradas no ecocardiograma.</p>
        <p>O cateterismo card&#xED;aco revelou art&#xE9;rias coron&#xE1;rias normais e &#xED;ndice card&#xED;aco de 2,36
L . min<sup>&#x2212;1</sup> . m<sup>&#x2212;2</sup> (valor normal, 2,6-4,2 L . min<sup>&#x2212;1</sup> .
m<sup>&#x2212;2)</sup>. As bi&#xF3;psias mioc&#xE1;rdicas apresentaram celularidade mista sem
fibrose ou qualquer outra forma de infiltra&#xE7;&#xE3;o. Os testes de detec&#xE7;&#xE3;o de DNA foram
negativos para v&#xED;rus do herpes simplex, herpesv&#xED;rus humano 6 (HHV-6), HHV-8,
citomegalov&#xED;rus, v&#xED;rus BK e v&#xED;rus Epstein-Barr. </p>
        <p>Os resultados dos testes de fun&#xE7;&#xE3;o pulmonar foram normais. Por&#xE9;m, a capacidade de
difus&#xE3;o mostrou-se um pouco diminu&#xED;da (PaO<sub>2</sub>/FiO<sub>2</sub> = 320).</p>
        <p>O hemograma apresentou par&#xE2;metros inflamat&#xF3;rios normais, eutireoidismo e n&#xED;vel de
pept&#xED;deo natriur&#xE9;tico cerebral de 963,6 pg/mL (valor normal, &lt; 100 pg/mL). Os
par&#xE2;metros renais e hep&#xE1;ticos, as prote&#xED;nas do complemento e o sedimento urin&#xE1;rio
estavam todos normais. O painel sorol&#xF3;gico foi negativo para HIV, s&#xED;filis,
<italic>Mycoplasma</italic> sp., <italic>Coxiella</italic> sp., citomegalov&#xED;rus,
v&#xED;rus Epstein-Barr, parvov&#xED;rus B19 e HHV-6. Os resultados dos testes para doen&#xE7;as
autoimunes foram normais.</p>
        <p>Os resultados da broncoscopia foram normais. O LBA apresentou celularidade normal,
rela&#xE7;&#xE3;o de linf&#xF3;citos CD4/CD8 diminu&#xED;da (0,7) e presen&#xE7;a maci&#xE7;a de macr&#xF3;fagos
espumosos (<xref ref-type="fig" rid="f06">Figura 3</xref>). O estudo microbiol&#xF3;gico
do LBA foi negativo. N&#xE3;o foram obtidas bi&#xF3;psias pulmonares transbr&#xF4;nquicas, em raz&#xE3;o
de taquicardia ventricular durante o exame.</p>
        <p>
<fig id="f06" orientation="portrait" position="float"><label>Figura 3</label><caption><title> Fotomicrografia mostrando macr&#xF3;fagos espumosos no LBA
(May-Gr&#xFC;mwald-Giemsa; aumento, 400&#xD7;).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-03-00313-gf03-pt"/></fig>
</p>
        <p>Foi iniciado o tratamento padr&#xE3;o, sem melhora. Foi ent&#xE3;o iniciado suporte inotr&#xF3;pico.
Por&#xE9;m, nenhuma melhora foi observada ao longo de uma semana. Na &#xE9;poca, tomou-se a
decis&#xE3;o de descontinuar a venlafaxina. Duas semanas depois, a TCAR revelou uma
melhora not&#xF3;ria, com a perman&#xEA;ncia de apenas alguns n&#xF3;dulos centrolobulares no lobo
inferior direito. Juntamente com essa recupera&#xE7;&#xE3;o radiol&#xF3;gica, verificou-se uma
melhora geral, e a FEVE foi at&#xE9; 35% na alta hospitalar.</p>
        <p>Quatro meses depois, a paciente apresentava FEVE pr&#xF3;xima &#xE0; normal (50%), classe
funcional I da NYHA, apresentando somente dilata&#xE7;&#xE3;o leve do ventr&#xED;culo esquerdo
(60/40 mm) e regurgita&#xE7;&#xE3;o mitral leve. A maioria dos medicamentos card&#xED;acos foi,
portanto, descontinuada.</p>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>V&#xE1;rios trabalhos relatam efeitos adversos relacionados &#xE0; venlafaxina. H&#xE1; relatos de
pneumonite intersticial aguda e subaguda<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>-</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> e tamb&#xE9;m de casos de pneumonia eosinof&#xED;lica,<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> embora os mecanismos envolvidos ainda n&#xE3;o estejam esclarecidos. </p>
        <p>O diagn&#xF3;stico da doen&#xE7;a pulmonar intersticial induzida por drogas &#xE9; dificultado por
sua inespecificidade cl&#xED;nica, por variabilidades individuais, pelo efeito de confus&#xE3;o
causado por comorbidades e pelo tratamento com m&#xFA;ltiplos medicamentos.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> Al&#xE9;m disso, foram descritos casos de insufici&#xEA;ncia card&#xED;aca aguda
induzida pela venlafaxina, alguns at&#xE9; mesmo em pacientes previamente h&#xED;gidos em uso
de regimes padronizados de dosagem.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Alguns autores relataram miocardiopatia dilatada e choque cardiog&#xEA;nico
em um paciente com fun&#xE7;&#xE3;o card&#xED;aca previamente normal, com recupera&#xE7;&#xE3;o da FEVE ap&#xF3;s a
descontinua&#xE7;&#xE3;o do medicamento.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Com o uso da Escala de Probabilidade de Rea&#xE7;&#xF5;es Adversas a Medicamentos,
proposta por Naranjo et al.,<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> encontrou-se uma prov&#xE1;vel liga&#xE7;&#xE3;o com a venlafaxina.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Embora o mecanismo de agress&#xE3;o card&#xED;aca ainda n&#xE3;o seja totalmente
compreendido, h&#xE1; relatos de inibi&#xE7;&#xE3;o da recapta&#xE7;&#xE3;o da noradrenalina pelo mioc&#xE1;rdio e
de bloqueio dos canais de s&#xF3;dio card&#xED;acos, ambos induzidos por drogas.<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>
</p>
        <p>A superfam&#xED;lia do citocromo P450 (CYP) est&#xE1; presente no tecido pulmonar humano e
participa da inativa&#xE7;&#xE3;o enzim&#xE1;tica de in&#xFA;meros xenobi&#xF3;ticos.<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup> Diferen&#xE7;as metab&#xF3;licas relacionadas a polimorfismos do CYP contribuem
para a variabilidade refletida em respostas a drogas e toxicidade
inesperada.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> Alguns autores mostraram que, entre 59 pacientes com doen&#xE7;a pulmonar
intersticial induzida por drogas, 54 (91,5%) apresentavam pelo menos um dos genes
variantes do CYP estudados.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> Em 87% dos pacientes, a presen&#xE7;a de tais genes mostrou-se relevante para
o perfil cl&#xED;nico.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
        <p>A venlafaxina &#xE9; um antidepressivo que &#xE9; metabolizado em O-desmetilvenlafaxina (ODV)
pela isoenzima CYP2D6 e, em menor escala, pela CYP3A4.<sup>(</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> Para in&#xFA;meras drogas psicotr&#xF3;picas, a CYP2D6 &#xE9; uma enzima de alta
afinidade/baixa capacidade cujos polimorfismos podem fenotipicamente determinar uma
metaboliza&#xE7;&#xE3;o lenta, prolongada ou r&#xE1;pida.<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup> Como uma variante menos funcional pode ser capaz de precipitar
manifesta&#xE7;&#xF5;es graves,<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> a administra&#xE7;&#xE3;o de venlafaxina em metabolizadores lentos de CYP2D6 ou a
coadministra&#xE7;&#xE3;o com inibidores de CYP2D6 traz o risco de ac&#xFA;mulo de f&#xE1;rmacos e
subsequente agress&#xE3;o celular/org&#xE2;nica.<sup>(</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup> Demonstrou-se que a <italic>Centella asiatica</italic> pode induzir
inibi&#xE7;&#xE3;o moderada a forte da CYP2D6<sup>(</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup> e que o <italic>Fucus vesiculosus</italic> pode tamb&#xE9;m inibir o complexo
enzim&#xE1;tico citocromo P450.<sup>(</sup>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup> Dessa forma, embora o perfil de CYP2D6 de nossa paciente n&#xE3;o tenha sido
testado, temos como hip&#xF3;tese que ela era uma metabolizadora lenta de CYP2D6 ou que a
a&#xE7;&#xE3;o inibit&#xF3;ria do uso concomitante de medicamentos fitoter&#xE1;picos contribuiu para o
ac&#xFA;mulo da venlafaxina, levando a toxicidade cardiopulmonar.</p>
        <p>A fosfolipidose induzida por drogas &#xE9; caracterizada pelo ac&#xFA;mulo intracelular de
fosfolip&#xED;dios em v&#xE1;rios tecidos corporais e pela forma&#xE7;&#xE3;o de corpos lamelares,
levando a uma apar&#xEA;ncia espumosa dos macr&#xF3;fagos &#xE0; microscopia de luz.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> Pode ser causada por mais de 50 f&#xE1;rmacos que compartilham uma estrutura
molecular espec&#xED;fica, com regi&#xF5;es hidrof&#xF3;bicas e hidrof&#xED;licas, denominados drogas
anfif&#xED;licas cati&#xF4;nicas.<sup>(</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup> A formula&#xE7;&#xE3;o de venlafaxina utilizada por nossa paciente foi analisada
pelo Departamento de Qu&#xED;mica Org&#xE2;nica, Universidade de Coimbra, Portugal. A paciente
estava tomando uma formula&#xE7;&#xE3;o da mistura rac&#xEA;mica de cloridrato de
(R/S)-1-[(2-dimetilamino)-1-(4-metoxifenil)etil]- ciclohexanol. Sua estrutura combina
um componente cati&#xF4;nico hidrof&#xED;lico (grupos amina terminal e &#xE1;lcool terci&#xE1;rio) com um
componente apolar hidrof&#xF3;bico (metoxila&#xE7;&#xE3;o do anel arom&#xE1;tico e grupo ciclohexil),
conferindo anfifilicidade.<sup>(</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup> Al&#xE9;m disso, tem propriedade cati&#xF4;nica,<sup>(</sup>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>)</sup> pois a ODV apresenta um grupo fenol ac&#xED;dico (proveniente da hidr&#xF3;lise
dos &#xE9;teres met&#xED;licos ligados ao anel arom&#xE1;tico) e o grupo amina pode sofrer grande
protona&#xE7;&#xE3;o intramolecular, tornando-se uma droga anfif&#xED;lica cati&#xF4;nica ao assumir a
forma <italic>zwitterion</italic> (grupos amina arom&#xE1;tica O- e amina H+). Esse fato,
associado ao contexto cl&#xED;nico e &#xE0; presen&#xE7;a maci&#xE7;a de macr&#xF3;fagos espumosos no LBA,
sugere fortemente um mecanismo de fosfolipidose induzida pela venlafaxina.</p>
        <p>Embora a fosfolipidose induzida por drogas possa ocorrer horas ou meses ap&#xF3;s o in&#xED;cio
do tratamento,<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> seus mecanismos exatos ainda n&#xE3;o est&#xE3;o totalmente esclarecidos. Os
lisossomos atuam como um local de ac&#xFA;mulo de drogas anfif&#xED;licas cati&#xF4;nicas e
fosfolip&#xED;dios por causa de sua liga&#xE7;&#xE3;o direta com as drogas anfif&#xED;licas cati&#xF4;nicas e
da inibi&#xE7;&#xE3;o das fosfolipases.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>,</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup> Como os lisossomos participam de uma grande variedade de processos
celulares, pode haver comprometimento do transporte i&#xF4;nico, fosforiliza&#xE7;&#xE3;o oxidativa,
heterofagia, autofagia, reciclagem de organelas, repara&#xE7;&#xE3;o da membrana celular e
regula&#xE7;&#xE3;o do ciclo celular. Tr&#xEA;s padr&#xF5;es reconhecidos de dano podem ocorrer:
fosfolipidose macrof&#xE1;gica (o mais comum), fosfolipidose celular parenquimatosa e
fosfolipidose localizada.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>
</p>
        <p>Outra caracter&#xED;stica t&#xED;pica da fosfolipidose induzida por drogas &#xE9; a sua
reversibilidade ap&#xF3;s a descontinua&#xE7;&#xE3;o da droga.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> Como os n&#xED;veis de fosfolip&#xED;dios se normalizam e ocorre efluxo da droga,
as altera&#xE7;&#xF5;es org&#xE2;nicas, funcionais e radiol&#xF3;gicas geralmente melhoram em semanas ou
meses.<sup>(</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup> A reversibilidade geralmente &#xE9; total, mas danos permanentes podem
diminuir em casos de les&#xE3;o org&#xE2;nica mais grave.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup>
</p>
        <p>O presente caso detalha a ocorr&#xEA;ncia de toxicidade cardiopulmonar, provavelmente
associada &#xE0; venlafaxina. O caso ocorreu em uma paciente previamente h&#xED;gida de 35 anos
de idade que foi submetida a investiga&#xE7;&#xE3;o exaustiva ap&#xF3;s a exclus&#xE3;o de outras
poss&#xED;veis causas. Apenas dois casos semelhantes foram relatados na
literatura.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>
</p>
        <p>Reconhecemos a administra&#xE7;&#xE3;o concomitante de dois medicamentos fitoter&#xE1;picos
sabidamente inibidores da isoenzima espec&#xED;fica do metabolismo da venlafaxina, o que
explicaria o ac&#xFA;mulo de venlafaxina e ODV a n&#xED;veis t&#xF3;xicos. A forte rela&#xE7;&#xE3;o temporal
entre a administra&#xE7;&#xE3;o da droga e as manifesta&#xE7;&#xF5;es cl&#xED;nicas e, inversamente, entre a
descontinua&#xE7;&#xE3;o da droga e a r&#xE1;pida melhora das altera&#xE7;&#xF5;es pulmonares e da fun&#xE7;&#xE3;o
card&#xED;aca fornece suporte adicional a essa hip&#xF3;tese. Por raz&#xF5;es &#xE9;ticas, n&#xE3;o foi feita
reexposi&#xE7;&#xE3;o &#xE0; venlafaxina. Ap&#xF3;s uma an&#xE1;lise objetiva, considerando-se a Escala de
Probabilidade de Rea&#xE7;&#xF5;es Adversas a Medicamentos de Naranjo,<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> foi feito o diagn&#xF3;stico de toxicidade cardiopulmonar induzida pela
venlafaxina. </p>
        <p>Uma fosfolipidose induzida por drogas poderia ser o mecanismo de toxicidade, pois a
venlafaxina &#xE9; uma droga anfif&#xED;lica cati&#xF4;nica em potencial, e tamb&#xE9;m porque havia
grandes quantidades de macr&#xF3;fagos espumosos no LBA, rela&#xE7;&#xE3;o de linf&#xF3;citos T CD4/CD8
diminu&#xED;da no sangue e no LBA e caracter&#xED;sticas consistentes com um padr&#xE3;o do subtipo
"fosfolipidose macrof&#xE1;gica".</p>
        <p>O presente caso destaca a import&#xE2;ncia da alta suspei&#xE7;&#xE3;o cl&#xED;nica para o reconhecimento
oportuno da toxicidade cardiopulmonar induzida por drogas, especialmente em casos de
doen&#xE7;a inicialmente inexplic&#xE1;vel. A descontinua&#xE7;&#xE3;o imediata da droga geralmente
resulta em not&#xE1;vel melhora cl&#xED;nica e do progn&#xF3;stico.</p>
      </sec>
    </body>
    <back>
      <ack>
        <title>Agradecimentos</title>
        <p>Os autores agradecem o Professor V&#xED;tor Sobral do Departamento de Qu&#xED;mica da
Universidade de Coimbra sua vital contribui&#xE7;&#xE3;o na an&#xE1;lise da estrutura qu&#xED;mica da
venlafaxina.</p>
      </ack>
      <fn-group>
        <fn fn-type="supported-by">
          <p>Apoio financeiro: Nenhum.</p>
        </fn>
        <fn id="fn03" fn-type="supported-by">
          <label>*</label>
          <p>Trabalho realizado no Servi&#xE7;o de Pneumologia, na Unidade de Tratamento de
Insufici&#xEA;ncia Card&#xED;aca Avan&#xE7;ada do Servi&#xE7;o de Cardiologia e no Servi&#xE7;o de
Anatomopatologia, Centro Hospitalar e Universit&#xE1;rio de Coimbra, Coimbra,
Portugal.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
